Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((5s)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)-2-thiophenecarboxamide
2. Credelio
1. 1369852-71-0
2. Lotilaner [inn]
3. Credelio
4. Heh4938d7k
5. Lotilaner (ema Epar: Veterinary)
6. (s)-5-[5-(3,4,5-trichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-3-methylthiophene-2-carboxylic Acid [(2,2,2-trifluoroethyl Carbamoyl) Methyl] Amide
7. 3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5s)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]thiophene-2-carboxamide
8. 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-
9. Lotilaner [usan:inn]
10. Unii-heh4938d7k
11. Lotilaner [mi]
12. Lotilaner (usan/inn)
13. Lotilaner [usan]
14. Lotilaner [green Book]
15. Chembl3707310
16. Schembl16860871
17. Dtxsid701027551
18. Ex-a3269
19. Ac-36763
20. Hy-116564
21. Cs-0065903
22. D11212
23. Q27279888
24. 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamide
Molecular Weight | 596.8 g/mol |
---|---|
Molecular Formula | C20H14Cl3F6N3O3S |
XLogP3 | 6.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 6 |
Exact Mass | 594.972565 g/mol |
Monoisotopic Mass | 594.972565 g/mol |
Topological Polar Surface Area | 108 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 868 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of flea and tick infestations.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
* Dogs:
This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).
* Cats:
This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).
QP53BE04
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
NDC Package Code : 17205-629
Start Marketing Date : 2023-08-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6306
Submission : 2019-04-30
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Alivira Animal Health Limited has emerged as India's largest and 1st Global integrated animal health company specialising in manufacturing of Active Pharmaceutical Ingredients (API...
Details:
Proceeds will be used for the U.S. commercialization of Xdemy (lotilaner), designed to target and kill Demodex mites causing Demodex blepharitis.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Tarsus Announces Pricing of $100.0 Million Public Offering
Details : Proceeds will be used for the U.S. commercialization of Xdemy (lotilaner), designed to target and kill Demodex mites causing Demodex blepharitis.
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 29, 2024
Details:
TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Brand Name: TP-05
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : Lotilaner
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarsus Reports Positive Results from Phase 2a Trial of TP-05 for Lyme Disease Prevention
Details : TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.
Brand Name : TP-05
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients w...
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Details:
The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 01, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
Details : The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease...
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2023
Details:
The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-05.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-0...
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Details:
Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blephari...
Details : Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Tarsus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Tarsus Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2023
Details:
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Brand Name: TP-05
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Lead Product(s) : Lotilaner
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.
Brand Name : TP-05
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
2-bromo-3-methyl-5- acetylthiophene
CAS Number : 859199-06-7
End Use API : Lotilaner
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experie...
methyl 5-acetyl-3-methylthiophene2-carboxylate
CAS Number : 2758907-87-6
End Use API : Lotilaner
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experie...
2,2,2-trifluoro-1-(3,4,5- trichlorophenyl)ethanone
CAS Number : 158401-00-4
End Use API : Lotilaner
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experie...
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?